OS Therapies Inc
OSTX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001795091
No open-market purchases or sales by OS Therapies Inc insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q3 2026, worth $4.64M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 17, 2026, 2:22 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | – | Mar 31, 2025 |
| Research and development | $16.4M | $2.84M |
| Selling, general and administrative | $12.3M | $3.97M |
| Operating income | -$28.7M | -$6.81M |
| Net income | -$28.8M | -$8.88M |
| EPS, basic | $-0.98 | $-0.88 |
| EPS, diluted | $-0.98 | $-0.88 |
| Weighted shares, basic | – | 12.4M |
| Weighted shares, diluted | 29.3M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025! | FY2024! |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | – | Mar 31, 2025 |
| Cash and equivalents | $269.8K | $5.53M |
| Total current assets | $332.9K | $5.53M |
| Property, plant and equipment | $2.49K | $5.27K |
| Intangible assets | $6.50M | – |
| Total assets | $6.84M | $5.54M |
| Accounts payable | $9.94M | $1.66M |
| Total current liabilities | $11.8M | $4.63M |
| Total liabilities | $11.9M | $4.73M |
| Shareholders' equity | -$6.10M | -$5.24M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | – | Mar 31, 2025 |
| Operating cash flow | -$14.2M | -$7.28M |
| Capital expenditures | $466.4K | – |
| Free cash flow | -$14.7M | – |
| Depreciation and amortization | $363.1K | – |
| Stock-based compensation | $4.27M | $268.3K |
| Investing cash flow | -$466.4K | – |
| Financing cash flow | $9.44M | $12.8M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 13, 2026 | 52.3M | +48.5% | SEC |
| Aug 12, 2026 | 46.1M | +44.6% | SEC |
| May 14, 2026 | 44.5M | +58.5% | SEC |
| Mar 26, 2026 | 39.5M | +82.5% | SEC |
| Nov 14, 2025 | 35.2M | +65.8% | SEC |
| Aug 13, 2025 | 31.9M | +52.7% | SEC |
| May 13, 2025 | 28.1M | +134.5% | SEC |
| Mar 28, 2025 | 21.7M | +80.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.